VYNE THERAPEUTICS
VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly sel... ective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20.
VYNE THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.vynetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650)486-1416
Email Addresses:
[email protected]
Total Funding:
159.8 M USD
Technology used in webpage:
SPF Amazon IPv6 Google Maps Google Maps API Amazon Virginia Region CPanel SSL OpenSSL Akamai Hosted NameBright
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-03-09 | Foamix | Foamix acquired by VYNE Therapeutics | N/A |
Investors List
Remeditex Ventures
Remeditex Ventures investment in Series C - VYNE Therapeutics
Presidio Partners
Presidio Partners investment in Series C - VYNE Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - VYNE Therapeutics
F-Prime Capital
F-Prime Capital investment in Series C - VYNE Therapeutics
venBio Partners
venBio Partners investment in Series C - VYNE Therapeutics
Aisling Capital
Aisling Capital investment in Series C - VYNE Therapeutics
Novo Holdings
Novo Holdings investment in Series C - VYNE Therapeutics
Vivo Capital
Vivo Capital investment in Series C - VYNE Therapeutics
Bay City Capital
Bay City Capital investment in Series C - VYNE Therapeutics
Presidio Partners
Presidio Partners investment in Series B - VYNE Therapeutics
Official Site Inspections
http://www.vynetherapeutics.com Semrush global rank: 10.18 M Semrush visits lastest month: 31
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago